List view / Grid view
A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
Researchers hope immunotherapy will prevent against overactive immune response...
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
Researchers aim to develop a new immunotherapy that could alter the immune reactions to food. The result: Extended relief from peanut allergies...
Researchers have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients whose tumours have certain genetic mutations...
Combined treatment with two cancer immunotherapy drugs significantly prolonged survival in aggressive cancer malignant mesothelioma...
Phase 1 data supports the use of image-guided therapy for difficult to treat cancer...
Improper use of antibiotics may have an unintended consequence of hampering cancer treatments...
Researchers have developed a biodegradable hydrogel scaffold system to release chemotherapeutic and immunotherapeutic drugs at the tumour site...
The FDA has approved Imfinzi for the treatment of patients with stage III non-small cell lung cancer whose tumours are not able to be surgically removed and whose cancer has not progressed after treatment...
Moffitt Cancer Center researchers have discovered that patients with desmoplastic melanoma are more responsive to immune-activating anti-PD-1/PD-L1 therapies than previously assumed.
Multiple sclerosis patients to have routine access to beta interferon drug, says NICE in new draft guidance.
A drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant...
Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.
General study identifies targetable pathway that induces immunosuppressive environment in colorectal cancer...
